C.MornJ.Camacho-CarranzaR.Prospro-GarcaO.Espinosa-AguirreJ
Taking Semaglutide GLP-1 outside of these guidelines, or without medical supervision, may expose clients to unnecessary risks such as gastrointestinal side effects, pancreatitis, or gallbladder issues
Chapters Transcript Created by This Video Content is available for informational and educational purposes only
For a broader look at the formulas in this category, visit our Healthy Aging Supplements collection
Wester continued, Given that the metabolic syndrome is a major driver of liver-related outcomes both in patients with MASLD and other chronic liver diseases such as alcohol-related liver disease or viral hepatitis C, there could be a similar effect of GLP1 agonists in patients with chronic liver diseases of any etiology with concomitant metabolic traits, such as type 2 diabetes. Using data from the Decoding the Epidemiology of LIVER disease Swedish cohort, researchers aimed to determine the long-term risk for major adverse liver outcomes (MALO) among patients with chronic liver disease and type 2 diabetes who either initiated (n = 1,026) or did not initiate (n = 15,633) GLP1 agonists
.jpg)
